CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway

Puntos clave

• Sorafenib resistance is influenced by the activation of the AKT/mTOR signaling pathway.
• CCDC137 plays a key role in modulating liver cancer cell responses to sorafenib treatment.
• Analysis of the mechanisms of resistance provides insights into potential treatments for hepatocellular carcinoma.
• Finding ways to overcome this resistance could significantly enhance treatment outcomes for patients with liver cancer.